Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 0.57 |
| ▸ | MAPK11 | Q15759 | 16/20 | 0.57 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.49 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1504670 | 0.91 | MAPK14 (0.47) | MAPK14MAPK11MAPK13MAPK12 | |
| SCHEMBL1504773 | 0.89 | MAPK14 (0.55) | MAPK14MAPK11MAPK13MAPK12 | |
| SCHEMBL1504478 | 0.84 | MAPK14 (0.56) | MAPK14MAPK11MAPK13MAPK12 | |
| SCHEMBL1504173 | 0.84 | MAPK14 (0.55) | MAPK14MAPK11MAPK13MAPK12 | |
| SCHEMBL1504494 | 0.82 | MAPK11 (0.60) | MAPK14MAPK11MAPK13MAPK12 | |
| SCHEMBL1504734 | 0.80 | MAPK14 (0.53) | MAPK14MAPK11MAPK13MAPK12 | |
| SCHEMBL1504628 | 0.80 | MAPK14 (0.46) | MAPK14MAPK11MAPK13MAPK12 | |
| SCHEMBL241982 | 0.80 | HDAC1 (0.68) | MAPK14MAPK11MAPK13MAPK12 | |
| SCHEMBL1504677 | 0.79 | BRD4 (0.59) | MAPK14MAPK11MAPK13MAPK12 | |
| SCHEMBL27795655 | 0.77 | HDAC1 (0.41) | MAPK14MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173684-B2 | Pyridone derivatives as p38α MAPK inhibitors | ASTELLAS PHARMA INC. (JP) | 2012-05-08 | — | — | US | disclosed |
| US-8173684-B2 | Pyridone derivatives as p38α MAPK inhibitors | ASTELLAS PHARMA INC. (JP) | 2012-05-08 | — | — | US | disclosed |
| US-8173684-B2 | Pyridone derivatives as p38α MAPK inhibitors | ASTELLAS PHARMA INC. (JP) | 2012-05-08 | — | — | US | disclosed |
| EP-2155683-B1 | PYRIDONE DERIVATIVES AS P38A MAPK INHIBITORS | ASTELLAS PHARMA INC (JP) | 2011-03-16 | — | — | EP | disclosed |
| US-20100063098-A1 | PYRIDONE DERIVATIVES AS P38A MAPK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2010-03-11 | — | — | US | disclosed |
| US-20100063098-A1 | PYRIDONE DERIVATIVES AS P38A MAPK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2010-03-11 | — | — | US | disclosed |
| US-20100063098-A1 | PYRIDONE DERIVATIVES AS P38A MAPK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063098-A1 | PYRIDONE DERIVATIVES AS P38A MAPK INHIBITORS | MAPK1, MAPK6, MAPK3 | MAPK14 25/4885MAPK11 33/4885MAPK13 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.